Symbicort Aerosol
Product Images NDC 50090-4510

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Symbicort (NDC 50090-4510). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Figure1bodytext)

A line graph showing percent change from baseline in predicted FEV1 over a 12-week period for different treatment groups, including SYMBICORT 160/4.5 mcg, budesonide 160 mcg, formoterol 4.5 mcg, budesonide plus formoterol, and placebo. The x-axis represents weeks, and the y-axis represents percent change. Symbols differentiate each treatment group's data points throughout the study duration.*

FDA Label Image

Figure 2 (Figure2bodytext)

A line graph showing the percent change from baseline in predose FEV1 over 12 weeks of treatment for four groups: SYMBICORT 80/4.5 mcg, Budesonide 80 mcg, Formoterol 4.5 mcg, and Placebo. The graph compares lung function improvements with time (weeks) on the x-axis and percent change on the y-axis.*

FDA Label Image

Figure 3 (Figure3bodytext)

A line graph depicting the percent change from baseline in FEV1 over 12 hours for different dosing regimens of SYMBICORT and its components. The x-axis represents time in hours from 0 to 12, and the y-axis shows percent change from baseline, ranging from -10 to 25%. Multiple lines compare SYMBICORT 160/4.5 mcg, budesonide 160 mcg alone, formoterol 4.5 mcg alone, their combination, and placebo.*

FDA Label Image

Figure 4 (Figure4bodytext)

A line graph depicting percent change from baseline in FEV1 over 12 hours for five treatment groups, including SYMBICORT 160/4.5 mcg, Budesonide 160 mcg, Formoterol 4.5 mcg, a combination treatment, and placebo. The x-axis shows hours post-treatment and the y-axis shows percent change in FEV1.*

FDA Label Image

Figure 5 (Figure5bodytext)

A line graph depicts changes from baseline in 1-hour post-dose FEV1 (L) over a 12-week period for two treatments: SYMBICORT 80/4.5 mcg (two inhalations twice daily) and Budesonide 80 mcg (two inhalations twice daily). The graph includes data points at multiple weeks with patient counts at each assessment noted below the graph.*

FDA Label Image

Figure 6 (Figure6bodytext)

A line graph showing percent change from baseline in pre-dose FEV1 over six months of treatment for different inhalation therapies including SYMBICORT MDI 160/4.5 mcg, Budesonide 160 mcg, Formoterol 4.5 mcg, Budesonide 160 mcg + Formoterol 4.5 mcg, and placebo. The x-axis represents months of treatment, and the y-axis shows percent change from baseline. Sample sizes for each treatment group are listed below the graph.*

FDA Label Image

Figure 7 (Figure7bodytext)

A line chart displaying percent change from baseline in 1-hour post-dose FEV1 over a 6-month period for different treatments, including SYMBICORT MDI 160/4.5 mcg, Budesonide 160 mcg, Formoterol 4.5 mcg, Budesonide plus Formoterol, and placebo. The x-axis represents months of treatment and the y-axis shows percent change from baseline. Sample sizes at each time point are provided below the chart.*

FDA Label Image

Budesonide Structural Formula (Image 01)

Chemical structure diagram showing the molecular structures of the active ingredients Budesonide and Formoterol Fumarate Dihydrate in Symbicort aerosol inhalation medication.*

FDA Label Image

Structural Fumarate (Image 02)

Chemical structure of Budesonide and Formoterol Fumarate Dihydrate displayed as molecular formula components with aromatic rings, hydroxyl groups, and associated chemical bonds.*

FDA Label Image

Figure 1 (Image 03)

Illustration showing a Symbicort aerosol inhaler with labeled parts including the counter, canister inside the inhaler, mouthpiece, strap, and mouthpiece cover.*

FDA Label Image

Figure 2 (Image 04)

Instructional illustration showing hands removing the mouthpiece cover from a Symbicort aerosol inhaler. The inhaler is held vertically, and arrows indicate the motion of pulling the cover off to prepare the device for use.*

FDA Label Image

Figure 3 (Image 05)

An instructional diagram showing a hand holding a red aerosol inhaler with the mouthpiece exposing spray release. The inhaler cap is removed and held below the mouthpiece. The spray is illustrated as dots emitted from the mouthpiece, demonstrating how to use the inhaler device, likely for respiratory medication administration.*

FDA Label Image

Figure 4 (Image 06)

An instructional illustration showing hands using a Symbicort inhaler aerosol device, with medication being released onto a forearm. The image demonstrates the actuation or priming of the inhaler, likely part of usage instructions for Symbicort aerosol inhaler.*

FDA Label Image

Figure 5 (Image 07)

Line art illustration showing a person using an inhaler device by placing the mouthpiece in their mouth and pressing down on the canister to release aerosol medication. The image demonstrates the correct inhalation technique for a respiratory aerosol product.*

FDA Label Image

Counter (arrow pointing to 80)

An illustration showing a dose counter dial for an inhalation aerosol device, marked from 0 to 120, with increments labeled at 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, and 120. The dial is currently pointing near 75.*

FDA Label Image

Counter (arrow pointing to 15)

Illustration of a dose counter for an inhaler, marked with numbers from 0 to 120 in increments of 10, showing a current count near 27. The gauge is circular with color-coded segments indicating remaining doses.*

FDA Label Image

Label Image (Lbl500904510)

SYMBICORT 80/4.5 inhalation aerosol label by A-S Medication Solutions. The label indicates each inhaler contains 60 inhalations, with each actuation delivering 80 micrograms of budesonide and 4.5 micrograms of formoterol fumarate dihydrate. Storage instructions specify 68 to 77 degrees Fahrenheit, with the inhaler stored mouthpiece down. The product is for oral inhalation use only and is prescription-only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.